Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
Why the study?
This analysis explored the relationship between office systolic blood pressure and cardiorenal outcomes with finerenone in the FIDELIO-DKD trial.
Does finerenone reduce primary kidney and secondary cardiovascular composite outcomes irrespective of baseline systolic blood pressure in patients with type 2 diabetes and chronic kidney disease?
Population
5669 patients with type 2 diabetes and chronic kidney disease receiving optimized renin-angiotensin system blockade
Comparison
Finerenone vs placebo across baseline office SBP quartiles
Design
Randomized trial post hoc analysis
Authors
Discussion
Loading...
Member takes
Implication
Supports finerenone use across SBP levels in T2D-CKD; confirms cardiorenal benefit largely independent of BP reduction.
Structured PICO
Does finerenone reduce primary kidney and secondary cardiovascular composite outcomes irrespective of baseline systolic blood pressure in patients with type 2 diabetes and chronic kidney disease?
P
Population
5,669 patients with type 2 diabetes, urine albumin-to-creatinine ratio 30 to 5000 mg/g, and estimated glomerular filtration rate of 25 to <75 mL/min per 1.73 m2 receiving optimized renin-angiotensin system blockade
I
Intervention
Finerenone
C
Comparator
Placebo
O
Outcome
Primary kidney composite outcomecomposite
Finerenone improves cardiorenal outcomes in patients with diabetic kidney disease irrespective of baseline systolic blood pressure, and this benefit is largely independent of its blood pressure-lowering effect.
Cite This Study
Ruilope et al. (2022) studied this question.